Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2

被引:41
作者
Godal, R
Keilholz, U
Uharek, L
Letsch, A
Asemissen, AM
Busse, A
Na, IK
Thiel, E
Scheibenbogen, C
机构
[1] St Elizabeth Oncol Inst, Dept Internal Med, Bratislava, Slovakia
[2] Dept Hematol Oncol & Transfus Med, Berlin, Germany
关键词
D O I
10.1182/blood-2005-07-2880
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There is considerable interest in immunotherapeutic approaches for lymphoma. The expression of proteinase inhibitor 9 (PI-9), a molecule that inactivates granzyme B, is considered an immune escape mechanism in lymphoma. Further, lymphomas frequently overexpress the antiapoptotic molecule bcl-2, which is able to inhibit perforin-dependent cytotoxic pathways. In this study, the impact of PI-9 and bcl-2 expression on the sensitivity of lymphomas to T- and natural killer (NK) cell-mediated cytotoxicity was analyzed. We found PI-9 expression in 10 of 18 lymphoma cell lines and in 9 of 14 primary lymphomas. Overexpression of bcl-2 was found in 8 of 18 cell lines and in 12 of 14 primary lymphomas. All lymphoma cells were sensitive to cytolysis by specific T cells and cytokine-activated NK cells, and no difference in sensitivity was observed with respect to PI-9 or bcl-2 expression. Cytolysis was mediated predominantly through perforin-dependent pathways despite expression of PI-9 and bcl-2. Interestingly, the majority of lymphoma cells were resistant to cytolysis by resting allogeneic INK cells. This was due to the failure of lymphomas to induce degranulation of resting NK cells. These results show that resistance to perforin-dependent pathways is not a relevant immune escape mechanism in lymphoma and therefore is unlikely to impair clinical outcome of immunotherapeutic approaches.
引用
收藏
页码:3205 / 3211
页数:7
相关论文
共 43 条
  • [1] Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes
    Azuma, T
    Otsuki, T
    Kuzushima, K
    Froelich, CJ
    Fujita, S
    Yasukawa, M
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (21) : 7402 - 7412
  • [2] Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma
    Bendandi, M
    Gocke, CD
    Kobrin, CB
    Benko, FA
    Sternas, LA
    Pennington, R
    Watson, TM
    Reynolds, CW
    Gause, BL
    Duffey, PL
    Jaffe, ES
    Creekmore, SP
    Longo, DL
    Kwak, LW
    [J]. NATURE MEDICINE, 1999, 5 (10) : 1171 - 1177
  • [3] Granzyme A loading induces rapid cytolysis and a novel form of DNA damage independently of caspase activation
    Beresford, PJ
    Xia, ZN
    Greenberg, AH
    Lieberman, J
    [J]. IMMUNITY, 1999, 10 (05) : 585 - 594
  • [4] Sensitive and viable identification of antigen-specific CD8+T cells by a flow cytometric assay for degranulation
    Betts, MR
    Brenchley, JM
    Price, DA
    De Rosa, SC
    Douek, DC
    Roederer, M
    Koup, RA
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 2003, 281 (1-2) : 65 - 78
  • [5] Syngeneic hematopoietic stem-cell transplantation for Non-Hodgkin's lymphoma: A comparison with allogeneic and autologous transplantation - The lymphoma working committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation
    Bierman, PJ
    Sweetenham, JW
    Loberiza, FR
    Taghipour, G
    Lazarus, HM
    Rizzo, JD
    Schmitz, N
    van Besien, K
    Vase, JM
    Horowitz, M
    Goldstone, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (20) : 3744 - 3753
  • [6] Selective regulation of apoptosis: the cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell death pathway
    Bird, CH
    Sutton, VR
    Sun, JR
    Hirst, CE
    Novak, A
    Kumar, S
    Trapani, JA
    Bird, PI
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (11) : 6387 - 6398
  • [7] Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system?
    Bladergroen, BA
    Meijer, CJLM
    ten Berge, RL
    Hack, CE
    Muris, JJF
    Dukers, DF
    Chott, A
    Kazama, Y
    Oudejans, JJ
    van Berkum, O
    Kummer, JA
    [J]. BLOOD, 2002, 99 (01) : 232 - 237
  • [8] SPI-CI and SPI-6 cooperate in the protection from effector cell-mediated cytotoxicity
    Bots, M
    Kolfschoten, IGM
    Bres, SA
    Rademaker, MTGA
    de Roo, GM
    Krüse, M
    Franken, KLMC
    Hahne, M
    Froelich, CJ
    Melief, CJM
    Offringa, R
    Medema, JP
    [J]. BLOOD, 2005, 105 (03) : 1153 - 1161
  • [9] Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
    Cartron, G
    Dacheux, L
    Salles, G
    Solal-Celigny, P
    Bardos, P
    Colombat, P
    Watier, H
    [J]. BLOOD, 2002, 99 (03) : 754 - 758
  • [10] CHIU VK, 1995, J IMMUNOL, V154, P2023